1. Home
  2. TNXP vs EIC Comparison

TNXP vs EIC Comparison

Compare TNXP & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNXP
  • EIC
  • Stock Information
  • Founded
  • TNXP 2007
  • EIC N/A
  • Country
  • TNXP United States
  • EIC United States
  • Employees
  • TNXP N/A
  • EIC N/A
  • Industry
  • TNXP Biotechnology: Pharmaceutical Preparations
  • EIC Finance/Investors Services
  • Sector
  • TNXP Health Care
  • EIC Finance
  • Exchange
  • TNXP Nasdaq
  • EIC Nasdaq
  • Market Cap
  • TNXP 335.6M
  • EIC 343.8M
  • IPO Year
  • TNXP N/A
  • EIC 2019
  • Fundamental
  • Price
  • TNXP $51.35
  • EIC $13.09
  • Analyst Decision
  • TNXP Buy
  • EIC Strong Buy
  • Analyst Count
  • TNXP 1
  • EIC 1
  • Target Price
  • TNXP $70.00
  • EIC $17.50
  • AVG Volume (30 Days)
  • TNXP 1.8M
  • EIC 360.3K
  • Earning Date
  • TNXP 08-11-2025
  • EIC 08-12-2025
  • Dividend Yield
  • TNXP N/A
  • EIC 18.36%
  • EPS Growth
  • TNXP N/A
  • EIC N/A
  • EPS
  • TNXP N/A
  • EIC 0.70
  • Revenue
  • TNXP $9,831,000.00
  • EIC $55,581,156.00
  • Revenue This Year
  • TNXP $22.87
  • EIC $37.84
  • Revenue Next Year
  • TNXP $711.66
  • EIC $23.33
  • P/E Ratio
  • TNXP N/A
  • EIC $18.78
  • Revenue Growth
  • TNXP N/A
  • EIC 56.39
  • 52 Week Low
  • TNXP $6.76
  • EIC $12.10
  • 52 Week High
  • TNXP $130.00
  • EIC $16.71
  • Technical
  • Relative Strength Index (RSI)
  • TNXP 55.76
  • EIC 53.16
  • Support Level
  • TNXP $42.12
  • EIC $12.10
  • Resistance Level
  • TNXP $69.97
  • EIC $13.15
  • Average True Range (ATR)
  • TNXP 6.06
  • EIC 0.23
  • MACD
  • TNXP 1.01
  • EIC 0.07
  • Stochastic Oscillator
  • TNXP 45.73
  • EIC 94.29

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

Share on Social Networks: